News | Drug-Eluting Balloons | September 20, 2019

Virtue Sirolimus-Eluting Balloon Earns FDA Breakthrough Device Designation

Virtue SEB becomes first non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease

Virtue Sirolimus-Eluting Balloon Earns FDA Breakthrough Device Designation

September 20, 2019 — Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Virtue Sirolimus-Eluting Balloon (SEB) in the treatment of below-the-knee (BTK) peripheral artery disease.

Peripheral artery disease (PAD) affects approximately 8.5 million people in the U.S and is growing dramatically in the elderly population.[1] BTK (infrapopliteal) atherosclerosis is the most common cause of critical limb ischemia (CLI), which is associated with a high rate of amputations and poor survival outcomes.[2] The treatment of BTK atherosclerotic disease is complex, as lesions in these small diameter arteries tend to be diffuse, long and often involve calcification. Currently approved therapeutic options are limited and have been shown to be marginally effective, leaving substantial unmet need for more effective treatment options for BTK atherosclerosis.

“Virtue SEB’s unique design enables delivery of sustained-release sirolimus during angioplasty without the need for coating or permanent implant. This highly differentiated design makes this product the ideal candidate for Breakthrough Device Designation in BTK peripheral artery disease,” said James P. Zidar, M.D., FACC, FSCAI, clinical professor of medicine, UNC Health Systems, physician-in-chief, Heart & Vascular Corporate. “Currently, there is a significant unmet need in the BTK stenosis treatment landscape. The presence of underlying comorbidities renders many patients unsuitable for bypass surgery. Angioplasty with plain balloons, which has been the default endovascular therapy for years, has a low success rate. Adding a proven anti-restenotic agent like sirolimus has the potential to enhance this treatment approach and drive better patient outcomes.”

Virtue SEB is a novel, first-in-class drug/device combination product that delivers a sustained-release sirolimus formulation directly to the artery during balloon angioplasty without the need for a coating. Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life-threatening or irreversibly debilitating diseases. Manufacturers are then able to offer patients and healthcare providers quicker access to new medical devices by expediting the development, assessment, and review process.

For more information: www.orchestrabiomed.com

 

References 

1. CDC. 2016. Peripheral Arterial Disease Fact Sheet [online] Available at: https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_pad.htm[Accessed 7 August 2019]

2. Fowkes F.G., Rudan D., Rudan I., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1329-40\


Related Content

News | Drug-Eluting Balloons

March 1, 2024 — Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) ...

Home March 01, 2024
Home
News | Drug-Eluting Balloons

October 30, 2023 — Boston Scientific Corporation on Friday announced positive 12-month results from the pivotal AGENT ...

Home October 30, 2023
Home
News | Drug-Eluting Balloons

September 14, 2023 — BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry ...

Home September 14, 2023
Home
News | Drug-Eluting Balloons

September 11, 2023 — The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease ...

Home September 11, 2023
Home
News | Drug-Eluting Balloons

July 14, 2023 — BIOTRONIK announced the one-year subgroup results from the investigator-initiated BIOPACT randomized ...

Home July 14, 2023
Home
News | Drug-Eluting Balloons

May 30, 2023 — Twelve-month results from the SELUTION SFA trial have been presented for the first time at the Japan ...

Home May 30, 2023
Home
News | Drug-Eluting Balloons

May 30, 2023 — The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for ...

Home May 30, 2023
Home
News | Drug-Eluting Balloons

May 12, 2023 — The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s novel ...

Home May 12, 2023
Home
News | Drug-Eluting Balloons

May 4, 2023 — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the ...

Home May 04, 2023
Home
News | Drug-Eluting Balloons

April 28, 2023 — Medtronic today shared additional 36-month data from the IN.PACT AV Access Study, as well as 48-month ...

Home April 28, 2023
Home
Subscribe Now